Navigation Links
Nile Therapeutics Announces Plans to Pursue a Post-Acute Indication in Heart Failure
Date:2/28/2011

SAN MATEO, Calif., Feb. 28, 2011 /PRNewswire/ -- Nile Therapeutics, Inc. (Nasdaq: NLTX), a biopharmaceutical company focused on the development of novel therapeutics for cardiovascular disease, announced plans to pursue a new indication in the field of heart failure.  Nile plans to develop cenderitide (formerly CD-NP) as an outpatient therapy to be delivered to acutely decompensated heart failure (ADHF) patients continuously for up to 90 days after discharge from the hospital.  This is a novel therapeutic space for natriuretic peptides that has been termed "post-acute."

Within 90 days of admission for ADHF, approximately 40% of patients return to the hospital. Post-acute patients need sustained cardiac and renal function support to prevent a recurrence of their acute symptoms. In multiple clinical trials in both acute and chronic heart failure patients, short-term infusion of cenderitide has been shown to have positive effects on cardiovascular and renal parameters. Nile believes that the continuous and extended infusion of cenderitide through a subcutaneous pump will provide patients with sustained symptomatic relief in the outpatient setting that could contribute to a reduction in post-acute hospitalizations and persistent improvement in cardiorenal functions.

"With over 1 million admissions per year in the U.S., at a cost of over $33 billion, ADHF is one of our country's most expensive health problems," said Richard B. Brewer, Nile's Executive Chairman. "We believe that cenderitide has an opportunity to address a true unmet need in heart failure, and could help reduce the overall cost of health care."

Nile recently had a productive meeting with the United States Food and Drug Administration (FDA) on the development of cenderitide as an extended subcutaneous therapy for a post-acute indication. Nile will seek a FDA Fast-Track Approval Designation fo
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Nile Therapeutics to Collaborate with Medtronic on Clinical Development of Cenderitide for Heart Failure and Renal Disease
2. Deston Therapeutics Stands By Safety and Efficacy of Auralgan After FDA Action
3. Silence Therapeutics Issued New U.S. Patent Covering Fundamental RNA Interference Technology Currently in Several Clinical Trials
4. Cornerstone Therapeutics to Host Fourth Quarter and Full Year 2010 Conference Call
5. Echo Therapeutics Reports Symphony™ tCGM System Ahead of Schedule
6. Orexigen® Therapeutics, Inc. Announces Upcoming Departure of Chief Financial Officer
7. Prime Therapeutics Vice President of Specialty Pharmacy Solutions Speaks at 16th Annual PBMI Drug Benefit Conference
8. Echo Therapeutics Announces Appointments to Board of Directors
9. Tarsa Therapeutics Completes Phase III Trial of its Oral Calcitonin for Treatment of Postmenopausal Osteoporosis and Initiates Phase II Trial in Osteoporosis Prevention
10. Cell Therapeutics, Inc. (CTI) to Report Fourth Quarter and Year-End 2010 Financial Results on February 16
11. Cephalon Signs Option Agreement to Acquire Assets from Alba Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Virginia , 11. Juli 2014 ... von Kameras für die molekulare Bildgebung, ... hat heute die CE-Zulassung für sein ... CE-Zeichen kann Dilon das Produkt jetzt ... auf den Großteil der europäischen Länder ...
(Date:7/10/2014)... , July 10, 2014  RESMED INC. (NYSE: ... fourth quarter and fiscal year ended June 30, 2014 results ... Exchange market close. A press release with ResMed,s results will ... company will host a webcast to discuss operating results and ... begin at 1:30 p.m. US Pacific Time and the live ...
(Date:7/10/2014)... , July 10, 2014   Ventana Medical Systems, ... announced it has entered into an agreement with Merck ... as EMD Serono in the United States ... collaborate with Merck KGaA,s biopharmaceutical division on the development ... undisclosed target using Ventana,s proprietary diagnostic assays. In alignment ...
Breaking Medicine Technology:Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3
... OncoSec Medical Incorporated (OTCBB:ONCS), which is developing ... to treat solid tumor cancers, today announced that ... and Lakeland Comprehensive Cancer Center in Lakeland, FL ... are screening patients for the Phase II metastatic ...
... International, Inc. (NASDAQ: BDSI ) announced that ... of further litigation in the patent infringement lawsuit previously ... that the case would be stayed pending resolution by ... proceedings and follows the recent rejection by the USPTO ...
Cached Medicine Technology:OncoSec Initiates Two Additional Clinical Sites for Phase II Metastatic Melanoma Trial 2OncoSec Initiates Two Additional Clinical Sites for Phase II Metastatic Melanoma Trial 3OncoSec Initiates Two Additional Clinical Sites for Phase II Metastatic Melanoma Trial 4Federal Court Grants Request by BioDelivery Sciences for Stay of MonoSol Litigation 2Federal Court Grants Request by BioDelivery Sciences for Stay of MonoSol Litigation 3
(Date:7/11/2014)... HealthDay Reporter THURSDAY, July ... HIV who was thought to be cured by immediate and ... levels of the AIDS-causing virus in her bloodstream, disappointed federal ... years old, had remained virus-free even though she stopped taking ... hoped her remission would open the door to a functional ...
(Date:7/11/2014)... Microbiology testing is a highly dynamic and rapidly ... expected to pose the biggest challenge to suppliers in ... to the ongoing spread of AIDS – still the ... factor leading to the upsurge of opportunistic infections, novel ... availability of immunosuppressants, among others. , Market maturity, ...
(Date:7/11/2014)... The report, “Specialty Synthetic Fibers & Glass ... 2018,” defines and segments the specialty synthetic fibers ... forecast of the volumes and values of types ... aramids, UHMW Polyethylene, carbon fiber, partially oxidized polyacrylonitrile ... PBO fiber, and liquid crystal polymer fiber and ...
(Date:7/11/2014)... 2014 Datalogic brings a new and ... hospital wide. With their new Gryphon GD4400 ... like the devastating MRSA, which claimed 5,500 lives, becomes ... 2D and the Gryphon GM4400-HC 2D readers can ... even read barcodes off of troublesome LCD monitors, smartphones, ...
(Date:7/11/2014)... 2014 Operators and owners ... in fuel costs now that model 2019 ... GHG standards are phasing in 2014-2018 ... themselves to install new features into their ... technologies , 2.    Efficient driveline components which reduce ...
Breaking Medicine News(10 mins):Health News:Mississippi Girl Thought Cured of HIV Shows Signs of Infection 2Health News:Mississippi Girl Thought Cured of HIV Shows Signs of Infection 3Health News:World Virology and Bacteriology Testing Sector Discussed in Comprehensive VPG Research Report Published at MarketPublishers.com 2Health News:World Virology and Bacteriology Testing Sector Discussed in Comprehensive VPG Research Report Published at MarketPublishers.com 3Health News:Specialty Synthetic Fibers & Glass Fiber Market Poised to Reach $20.1 Billion at a CAGR of 5.2% by 2018 – Report by MarketsandMarkets 2Health News:Specialty Synthetic Fibers & Glass Fiber Market Poised to Reach $20.1 Billion at a CAGR of 5.2% by 2018 – Report by MarketsandMarkets 3Health News:Specialty Synthetic Fibers & Glass Fiber Market Poised to Reach $20.1 Billion at a CAGR of 5.2% by 2018 – Report by MarketsandMarkets 4Health News:Stop Spreading Disease with the New Disinfectant-Ready Bar Code Scanner 2Health News:Stop Spreading Disease with the New Disinfectant-Ready Bar Code Scanner 3Health News:LeaseQ Agrees the Latest Round of Greenhouse Gas Rules Could Increase the Cost of Truck Acquisition and Maintenance 2Health News:LeaseQ Agrees the Latest Round of Greenhouse Gas Rules Could Increase the Cost of Truck Acquisition and Maintenance 3
... on mountain biking it is observed that it could decrease ... Innsbruck, Austria,// presented his findings of a study that looked ... 30 non-bikers took part in the study. An extreme biker ... a day, six days a week, and more than 3,000 ...
... good coping style helps women to deal positively with breast ... a difference in the fight against cancer. Researchers in the ... that stress, mental outlook and coping style are all relevant ... ,They found that up to 44 per cent ...
... than conventional treatment for managing asthma attacks. Several ... cells known eosinophils increase// in the airways. Researchers ... targeting this build up of eosinophils in sputum ... attack. ,The conventional treatment consists of ...
... that doctors should use lower thresholds when treating high ... minorities.// Researchers at St George's Hospital, Georgia have carried ... of various ethnic origins, looking at their heart disease ... African origin have the lowest risk of heart disease, ...
... is observed that a drug used to treat inflammation ... meningitis. Dexamethasone is an effective steroid when given with ... diagnosed with bacterial meningitis is high, especially in patients ... Center in Amsterdam conducted a study to determine if ...
... According to a new study, researchers have observed that ... year after angioplasty had a decreased risk of problems. ... called a stent into a blocked coronary artery.// It's ... However, one complication that often occurs when such percutaneous ...
Cached Medicine News:
Alkaline phosphatase FS (DGKC). For determination of alkaline phosphatase (ALP) in serum or plasma. For Hitachi 717. Controls: Trulab N and Trulab P....
Intended for the quantitative determination of alkaline phosphatase activity in serum or plasma. Kinetic reaction. 405 nm wavelength. 830 U/L at 30C linearity. Single vial, dry powder reagent....
Auto LDL-Cholesterol, automated analyzer test kits....
Storage temperature: 2 - 8C, linearity: 0 - 25 mg/dL, expected value: male: 3.5 - 7.0 mg/dL and female: 2.5 - 6.0 mg/dL. Available with calibrator and number of test 500....
Medicine Products: